Enhancing vector bioprocess scalability 2022

Tackling scalability challenges in AAV manufacture

Cell & Gene Therapy Insights 2022; 8(1), 25–28

10.18609/cgti.2022.014

Published: 31 January 2022
Interview
Kyle Grant

Kyle Grant is a trained PhD chemical engineer with a concentration in molecular virology. Kyle has extensive experience in the molecular analysis of virus host cell interactions, as well as innovation around commercial grade unit operations to support CMC activities for the application of viral vectors in gene therapy. This multi-scale approach allows for comprehensive insight into the development of methods for provision and release of novel drug candidates to address the unmet need for patients where there is no available cure.